Advertisement

Surface Epithelial Tumors of the Ovary

  • Jeffrey D. SeidmanEmail author
  • Kathleen R. Cho
  • Brigitte M. Ronnett
  • Robert J. Kurman
Reference work entry

Abstract

Worldwide, ovarian cancer is the sixth most common cancer in women and the seventh most common cause of cancer death. There are about 204,000 new cases and 125,000 deaths annually [29]. In most Western countries, ovarian carcinoma is the fifth most common malignancy and ranks fourth in cancer mortality. In the Western hemisphere, it accounts for 4% of cancer in women and is the most frequent cause of death due to gynecological cancer. In US women, ovarian cancer ranks ninth in incidence and fifth in mortality, and accounts for 3% of cancers diagnosed and 5% of cancer deaths. It is estimated that in the United States in 2010, there were 21,880 new ovarian cancer cases and 13,850 deaths [137]. Approximately 1.4% of American women will develop ovarian cancer in their lifetime. In general, the disease is more common in industrialized countries where parity is lower, but there are notable exceptions such as Japan which has a low parity and low rate of ovarian cancer. The incidence varies widely among different ethnic groups. The lifetime risk varies widely from 0.45% in Japan to 1.7% in Sweden. Annual incidence rates of ovarian cancer range from less than 5 per 100,000 women in The Gambia, Brazil, Thailand, Algeria, and India, to greater than 13 per 100,000 in the United Kingdom, United States, Germany, and Scandinavia. In the United States, based on SEER (Surveillance, Epidemiology, and End Results (US National Cancer Institute)) data, the rate is 13.5 per 100,000 (2000–2004) [340]. Scandinavia has one of the highest annual incidence rates at greater than 16 per 100,000 women [337]. There has been little change in incidence over the past few decades with a few exceptions: in Korea, the age-standardized incidence increased by 25% from 3.8 to 4.7 per 100,000 from 1993 to 2002 [57], and over the same period, the incidence in Israel decreased by nearly one third from 9.6 to 6.6 per 100,000 [217]. The extent to which changes in diagnostic criteria or calculation methods may account for these changes is unclear. However, in the United States, changing the age-adjustment to the 2000 standard has artificially increased the incidence of ovarian cancer by about 20% [9]. In addition, the incidence of ovarian carcinoma appears to have decreased as peritoneal and tubal carcinomas have increased [110]. This may reflect a recent increase in the awareness of peritoneal and particularly tubal carcinomas among pathologists. Accordingly, relatively small changes in the incidence of ovarian carcinoma are probably due to these factors. Migration studies have shown that ovarian cancer rates approach those of the place of immigration rather than the place of emigration, suggesting a significant environmental component to ovarian cancer risk.

Notes

Acknowledgment

The authors thank Jonathan A. Cosin, M.D., for reviewing the clinical portions of the chapter, and Peter Russell, M.D., for his contributions in previous editions.

References

  1. 1.
    Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23:110–118PubMedCrossRefGoogle Scholar
  2. 2.
    Agoff SN, Mendelin JE, Grieco VS et al (2002) Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or –2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 26:171–178PubMedCrossRefGoogle Scholar
  3. 3.
    Akahne T, Sekizawa A, Okuda T et al (2005) Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol 24:369–376CrossRefGoogle Scholar
  4. 4.
    Akeson M, Jakobsen A-M, Zetterqvist BM et al (2009) A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer 19:116–123PubMedCrossRefGoogle Scholar
  5. 5.
    Akeson M, Zetterqvist BM, Dahllof K et al (2008) Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer 18:453–459PubMedCrossRefGoogle Scholar
  6. 6.
    Ali-Fehmi R, Khalifeh I, Bandyopadhyay S et al (2006) Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis. Int J Gynecol Pathol 25:223–229PubMedCrossRefGoogle Scholar
  7. 7.
    Allison KH, Swisher EM, Kerkering KM et al (2008) Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary? Int J Gynecol Pathol 27:10–17PubMedCrossRefGoogle Scholar
  8. 8.
    Alphs HH, Zahurak ML, Bristow RE et al (2006) Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 103:1048–1053PubMedCrossRefGoogle Scholar
  9. 9.
    American Cancer Society (2008) Cancer facts and figures. American Cancer Society, AtlantaGoogle Scholar
  10. 10.
    Andersen MR, Goff BA, Lowe KA et al (2008) Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 113:484–489PubMedCrossRefGoogle Scholar
  11. 11.
    Arboleda MJ, Lyons JF, Kabbinavar FF et al (2003) Overexpression of AKT2/protein kinase beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63:196–206PubMedGoogle Scholar
  12. 12.
    Armes JE, Lourie R, de Silva M et al (2005) Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24:363–368PubMedCrossRefGoogle Scholar
  13. 13.
    Athavale R, Thomakos N, Godfrey K et al (2007) The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer 17:1025–1030PubMedCrossRefGoogle Scholar
  14. 14.
    Ayhan A, Al RA, Baykal C et al (2004) The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer 14:51–56PubMedCrossRefGoogle Scholar
  15. 15.
    Ayhan A, Gultekin M, Dorsun P et al (2008) Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? Gynecol Oncol 108:428–432PubMedCrossRefGoogle Scholar
  16. 16.
    Ayhan A, Gultekin M, Taskiran C et al (2007) Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 17:68–75PubMedCrossRefGoogle Scholar
  17. 17.
    Ayhan A, Guven ESG, Guven S et al (2005) Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 98:439–445PubMedCrossRefGoogle Scholar
  18. 18.
    Ayhan A, Kurman RJ, Vang R et al (2009) Defining the cut point between low grade and high grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedCrossRefGoogle Scholar
  19. 19.
    Ayhan A, Taskiran C, Yigit-Celik N et al (2006) Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Int J Gynecol Cancer 16:484–489PubMedCrossRefGoogle Scholar
  20. 20.
    Baker PM, Oliva E (2005) Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol 24:39–55PubMedGoogle Scholar
  21. 21.
    Baldwin RL, Nemeth E, Tran H et al (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–5333PubMedGoogle Scholar
  22. 22.
    Barda G, Menczer J, Chetrit A et al (2004) Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 190:1039–1045PubMedCrossRefGoogle Scholar
  23. 23.
    Bedrosian I, Lu KH, Verschraegen C et al (2004) Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23:2648–2657PubMedCrossRefGoogle Scholar
  24. 24.
    Bell DA, Longacre TA, Prat J et al (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35:934–948PubMedCrossRefGoogle Scholar
  25. 25.
    Bell KA, Sehdev AES, Kurman RJ (2001) Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 25:419–432PubMedCrossRefGoogle Scholar
  26. 26.
    Bloss JD, Brady MF, Liao SY et al (2003) Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma – A Gynecologic Oncology Group Study. Gynecol Oncol 89:148–154PubMedCrossRefGoogle Scholar
  27. 27.
    Bommer GT, Gerin I, Feng Y et al (2007) p53-mediated activation of miRNA34 candidate tumor suppressor genes. Curr Biol 17:1298–1307PubMedCrossRefGoogle Scholar
  28. 28.
    Bonome T, Lee JY, Park DC et al (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65:10602–10612PubMedCrossRefGoogle Scholar
  29. 29.
    Boyle P, Levin B (eds) (2008) World cancer report 2008. World Health Organization, LyonGoogle Scholar
  30. 30.
    Bradley RF, Stewart JH, Russell GB et al (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30:551–559PubMedCrossRefGoogle Scholar
  31. 31.
    Brinkmann D, Ryan A, Ayhan A et al (2004) A molecular genetic and statistical approach for the diagnosis of dual-site cancers. J Natl Cancer Inst 96:1441–1446PubMedCrossRefGoogle Scholar
  32. 32.
    Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070–1076PubMedCrossRefGoogle Scholar
  33. 33.
    Bristow RE, Eisenhauer EL, Santillan A et al (2007) Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104:480–490PubMedCrossRefGoogle Scholar
  34. 34.
    Bristow RE, Gossett DR, Shook DR et al (2002) Recurrent micropapillary serous carcinoma: the role of secondary cytoreductive surgery. Cancer 95:791–800PubMedCrossRefGoogle Scholar
  35. 35.
    Brown E, Stewart M, Rye T et al (2004) Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 100:2148–2153PubMedCrossRefGoogle Scholar
  36. 36.
    Brustmann H (2007) Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1 and outcome. Int J Gynecol Pathol 26:147–153PubMedCrossRefGoogle Scholar
  37. 37.
    Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary. A distinctive low- grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20:1319–1330PubMedCrossRefGoogle Scholar
  38. 38.
    Buys SS, Partridge E, Greene MH et al (2005) Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193:1630–1639PubMedCrossRefGoogle Scholar
  39. 39.
    Cameron RI, Ashe P, O’Rourke DM et al (2003) A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 22:272–276PubMedCrossRefGoogle Scholar
  40. 40.
    Campbell IG, Russell SE, Choong DY et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681PubMedCrossRefGoogle Scholar
  41. 41.
    Cannistra SA (2007) BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. Clin Cancer Res 13:7225–7227PubMedCrossRefGoogle Scholar
  42. 42.
    Carcangiu ML, Peissel B, Pasini B et al (2006) Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 30:1222–1230PubMedCrossRefGoogle Scholar
  43. 43.
    Carcangiu ML, Radice P, Manoukian S et al (2004) Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 23:35–40PubMedCrossRefGoogle Scholar
  44. 44.
    Casey MJ, Synder C, Bewtra C et al (2005) Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 97:457–467PubMedCrossRefGoogle Scholar
  45. 45.
    Catasus L, Bussaglia E, Rodriguez I et al (2004) Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35:1360–1368PubMedCrossRefGoogle Scholar
  46. 46.
    Catasus L, Gallardo A, Cuatrecasas M et al (2008) PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Modern Pathol 21:131–139Google Scholar
  47. 47.
    Cathro HP, Stoler MH (2005) The utility of calretinin, inhibin and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 36:195–201PubMedCrossRefGoogle Scholar
  48. 48.
    Chambers SK (2005) Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved. J Natl Cancer Inst 97:548–549PubMedCrossRefGoogle Scholar
  49. 49.
    Chan JK, Teoh D, Hu JM et al (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376PubMedCrossRefGoogle Scholar
  50. 50.
    Chan JK, Tian C, Monk B et al (2008) Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112:2202–2210PubMedCrossRefGoogle Scholar
  51. 51.
    Chang SJ, Ryu HS, Chang KH et al (2008) Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand 87:476–481PubMedCrossRefGoogle Scholar
  52. 52.
    Chen S, Leitao MM, Tornos C et al (2005) Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Modern Pathol 18:903–911CrossRefGoogle Scholar
  53. 53.
    Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333PubMedCrossRefGoogle Scholar
  54. 54.
    Cheng EJ, Kurman RJ, Wang M et al (2004) Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 84:778–784PubMedCrossRefGoogle Scholar
  55. 55.
    Chiesa-Vottero AG, Malpica A, Deavers MT et al (2007) Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 26:328–333PubMedCrossRefGoogle Scholar
  56. 56.
    Cho KR, Shih IM (2009) Ovarian Cancer. Annu Rev Pathol Mech Dis 4:287–313CrossRefGoogle Scholar
  57. 57.
    Chung HH, Hwang SY, Jung KW et al (2007) Ovarian cancer incidence and survival in Korea. Int J Gynecol Cancer 17:595–600PubMedCrossRefGoogle Scholar
  58. 58.
    Cliby WA, Aletti GD, Wilson TO et al (2006) Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 103:797–801PubMedCrossRefGoogle Scholar
  59. 59.
    Colgan TJ (2003) Challenges in the early diagnosis and staging of fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol 22:109–120PubMedCrossRefGoogle Scholar
  60. 60.
    Colgan TJ, Boerner SL, Murphy J et al (2002) Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85:397–403PubMedCrossRefGoogle Scholar
  61. 61.
    Colgan TJ, Murphy J, Cole DEC et al (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25:1283–1289PubMedCrossRefGoogle Scholar
  62. 62.
    Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRefGoogle Scholar
  63. 63.
    Comin CE, Saieva C, Messerini L (2007) h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 31:1139–1148PubMedCrossRefGoogle Scholar
  64. 64.
    Connolly DC, Bao R, Nikitin AY et al (2003) Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63:1389–1397PubMedGoogle Scholar
  65. 65.
    Cosary CL (2007) Chapter 16: Cancer of the ovary. In: Ries LAG et al (eds) SEER survival monograph. Cancer survival among adults. US SEER program, 1988-2001. Patient and tumors characteristics. National Cancer Institute, NIH publication no. 07-6215Google Scholar
  66. 66.
    Cuatrecasas M, Catasus L, Palacios J et al (2009) Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol 33:556–567PubMedCrossRefGoogle Scholar
  67. 67.
    Cuatrecasas M, Villanueva A, Matias-Guiu X et al (1997) K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRefGoogle Scholar
  68. 68.
    Cusido M, Balaguero L, Hernandez G et al (2007) Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 104:617–622PubMedCrossRefGoogle Scholar
  69. 69.
    Davidson B, Skrede M, Silins I et al (2007) Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110:1264–1271PubMedCrossRefGoogle Scholar
  70. 70.
    Deavers MT, Gershenson DM, Tortolero-Luna G et al (2002) Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol 26:1129–1141PubMedCrossRefGoogle Scholar
  71. 71.
    Demopoulos RI, Aronov R, Mesia A (2001) Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol 20:128–132PubMedCrossRefGoogle Scholar
  72. 72.
    Dent J, Hall GD, Wilkinson N et al (2003) Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 88:1578–1583PubMedCrossRefGoogle Scholar
  73. 73.
    Di Cristofano A, Ellenson LH (2007) Endometrial carcinoma. Annu Rev Pathol 2:57–85PubMedCrossRefGoogle Scholar
  74. 74.
    Diebold J, Seemuller F, Lohrs U (2003) K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest 83:251–258PubMedGoogle Scholar
  75. 75.
    Dinulescu DM, Ince TA, Quade BJ et al (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63–67PubMedCrossRefGoogle Scholar
  76. 76.
    Djordjevic B, Malpica A (2010) Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases. Am J Surg Pathol 34:1–9PubMedCrossRefGoogle Scholar
  77. 77.
    Dube V, Roy M, Plante M et al (2005) Mucinous ovarian tumors of mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol 24:138–146PubMedCrossRefGoogle Scholar
  78. 78.
    Dusenbery KE, Bellairs EE, Potish RA et al (2005) Twenty-five year outcome of sequential abdominal radiotherapy and melphalan: implications for future management of epithelial carcinoma of the ovary. Gynecol Oncol 96:307–313PubMedCrossRefGoogle Scholar
  79. 79.
    Earle CC, Schrag D, Neville BA et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Nat Cancer Inst 98:172–180PubMedCrossRefGoogle Scholar
  80. 80.
    Eichorn JH, Bell DA, Young RH et al (1999) Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 23:397–409CrossRefGoogle Scholar
  81. 81.
    Eichorn JH, Young RH (2004) Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 28:453–463CrossRefGoogle Scholar
  82. 82.
    Eichorn JH, Young RH, Clement PB et al (2002) Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 26:1243–1258CrossRefGoogle Scholar
  83. 83.
    Eisenkop SM, Spirtos NM, Lin W-CM (2006) “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103:329–335PubMedCrossRefGoogle Scholar
  84. 84.
    Elishaev E, Gilks CB, Miller D et al (2005) Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol 29:281–294PubMedCrossRefGoogle Scholar
  85. 85.
    Enomoto T, Weghorst CM, Inoue M et al (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777–785PubMedGoogle Scholar
  86. 86.
    Euscher ED, Malpica A, Deavers MT et al (2005) Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 29:1074–1078PubMedGoogle Scholar
  87. 87.
    Euscher ED, Silva EG, Deavers MT et al (2004) Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol 28:1217–1223PubMedCrossRefGoogle Scholar
  88. 88.
    Finch A, Beiner B, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185–192PubMedCrossRefGoogle Scholar
  89. 89.
    Flesken-Nikitin A, Choi KC, Eng JP et al (2003) Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63:3459–3463PubMedGoogle Scholar
  90. 90.
    Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. WHO, GenevaGoogle Scholar
  91. 91.
    Fuji H, Matsumoto T, Yoshida M et al (2002) Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability. Hum Pathol 33:421–428CrossRefGoogle Scholar
  92. 92.
    Fujimara M, Hidaka T, Kataoka K et al (2001) Absence of estrogen receptor–[alpha] expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 25:667–672CrossRefGoogle Scholar
  93. 93.
    Fujita M, Enomoto T, Wada H et al (1996) Application of clonal analysis-differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Am J Clin Pathol 105:350–359PubMedGoogle Scholar
  94. 94.
    Fujita M, Enomoto T, Yoshino K et al (1995) Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64:361–366PubMedCrossRefGoogle Scholar
  95. 95.
    Furuya M, Suyama T, Usui H et al (2007) Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 38:1676–1687PubMedCrossRefGoogle Scholar
  96. 96.
    Gaarenstroom KN, van der Hiel B, Tollenaar RAEM et al (2006) Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16(suppl 1):54–59PubMedCrossRefGoogle Scholar
  97. 97.
    Gadducci A, Conte PF (2008) Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int J Gynecol Cancer 18:943–953PubMedCrossRefGoogle Scholar
  98. 98.
    Gamallo C, Palacios J, Moreno G et al (1999) beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, Clinicopathological features, and clinical outcome. Amer J Pathol 155:527–536CrossRefGoogle Scholar
  99. 99.
    Garg R, Zahurak ML, Trimble EL et al (2005) Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol 99:65–70PubMedCrossRefGoogle Scholar
  100. 100.
    Gayther SA, Mangion J, Russell P et al (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103–105PubMedCrossRefGoogle Scholar
  101. 101.
    Geisler JP, Goodheart MJ, Sood AK et al (2003) Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98:2199–2206PubMedCrossRefGoogle Scholar
  102. 102.
    Gemignani ML, Schlaerth AC, Bogomolniy F et al (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90:378–381PubMedCrossRefGoogle Scholar
  103. 103.
    Gershenson DM, Sun CC, Lu KH et al (2006) Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361–368PubMedCrossRefGoogle Scholar
  104. 104.
    Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23:200–205PubMedCrossRefGoogle Scholar
  105. 105.
    Gilks CB, Alkushi A, Yue JJW et al (2003) Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol 22:29–36PubMedCrossRefGoogle Scholar
  106. 106.
    Gilks CB, Ionescu DN, Kalloger SE et al (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39:1239–1251PubMedCrossRefGoogle Scholar
  107. 107.
    Gilks CB, Kobel M, Kalloger SE et al (2009) Significant differences in tumor cell type in early versus advanced stage ovarian carcinoma. Modern Pathol 22(S1):215AGoogle Scholar
  108. 108.
    Goldstein NS, Ceniza N (2000) Ovarian micropapillary serous borderline tumors: clinicopathologic features and outcome of seven surgically staged patients. Am J Clin Pathol 114:380–386PubMedCrossRefGoogle Scholar
  109. 109.
    Gomes CP, Andrade LALA (2006) PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. Int J Gynecol Cancer 16(suppl1):254–258PubMedCrossRefGoogle Scholar
  110. 110.
    Goodman MT, Shvetzov YB (2009) Incidence of ovarian, peritoneal and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev 18:132–139PubMedCrossRefGoogle Scholar
  111. 111.
    Granstrom C, Sundquist J, Hemminki K (2008) Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer 98:199–205PubMedCrossRefGoogle Scholar
  112. 112.
    Gu J, Roth LM, Younger C et al (2001) Molecular evidence for the independent origin of extraovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 93:1122–1123CrossRefGoogle Scholar
  113. 113.
    Gutgemann I, Lehman N, Jackson PK et al (2008) Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Modern Pathol 21:445–454CrossRefGoogle Scholar
  114. 114.
    Guth U, Huang DJ, Bauer G et al (2007) Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 110:1272–1280PubMedCrossRefGoogle Scholar
  115. 115.
    Halperin R, Zehavi S, Langer R et al (2001) Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 11:403–408PubMedCrossRefGoogle Scholar
  116. 116.
    Han G, Gilks CB, Leung S et al (2008) Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol 32:955–964PubMedCrossRefGoogle Scholar
  117. 117.
    Harter P, Gnauert K, Hils R et al (2007) Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17:1238–1244PubMedCrossRefGoogle Scholar
  118. 118.
    Hashi A, Yuminamochi T, Murata S-I et al (2003) Wilms tumor gene reactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22:374–377PubMedCrossRefGoogle Scholar
  119. 119.
    Heintz APM, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. In: 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 95(Suppl 1):S161–S192CrossRefGoogle Scholar
  120. 120.
    Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al (2006) A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 94:904–913PubMedCrossRefGoogle Scholar
  121. 121.
    Heller DS, Murphy P, Westhoff C (2005) Are germinal inclusion cysts markers of ovulation? Gynecol Oncol 96:496–499PubMedCrossRefGoogle Scholar
  122. 122.
    Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J et al (2007) Serum CA125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 25:1383–1389PubMedCrossRefGoogle Scholar
  123. 123.
    Hess LM, Benham-Hutchins M, Herzog TJ et al (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17:561–570PubMedCrossRefGoogle Scholar
  124. 124.
    Highlander B, Repasky E, Shrikant P et al (2006) Expression of Wilm’s tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol 101:12–17CrossRefGoogle Scholar
  125. 125.
    Ho CL, Kurman RJ, Dehari R et al (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64:6915–6918PubMedCrossRefGoogle Scholar
  126. 126.
    Hogg R, Scurry J, Kim SN et al (2007) Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 106:44–51PubMedCrossRefGoogle Scholar
  127. 127.
    Holland WW, Stewart S, Masseria C (2006) Policy brief: screening in Europe. World Health Organization; European Observatory on Health Systems and Policies. http://www.euro.who.int/Document/E88698.pdf. Accessed 9 Feb 2008
  128. 128.
    Hough CD, Cho KR, Zonderman AB et al (2001) Coordinately up-regulated genes in ovarian cancer. Cancer Res 61:3869–3876PubMedGoogle Scholar
  129. 129.
    Hough CD, Sherman-Baust CA, Pizer ES et al (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60:6281–6287PubMedGoogle Scholar
  130. 130.
    Howell NR, Zheng W, Cheng L et al (2007) Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol 26:134–140PubMedCrossRefGoogle Scholar
  131. 131.
    Hsu CY, Bristow R, Cha MS et al (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10:6432–6436PubMedCrossRefGoogle Scholar
  132. 132.
    Hsu C-Y, Kurman RJ, Vang R et al (2005) Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol 36:1049–1054PubMedCrossRefGoogle Scholar
  133. 133.
    Ichikawa Y, Nishida M, Suzuki H et al (1994) Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33–35PubMedGoogle Scholar
  134. 134.
    Jaaback KS, Ludeman L, Clayton NL et al (2006) Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer 16(suppl1):123–128PubMedCrossRefGoogle Scholar
  135. 135.
    Jaeger W, Ackermann S, Kessler H et al (2001) The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol 83:286–291PubMedCrossRefGoogle Scholar
  136. 136.
    Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  137. 137.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. American Cancer Society, Inc. doi:10.1002/caac.20073. Accessed July 21 2010Google Scholar
  138. 138.
    Jensen KC, Mariappan MR, Putcha GV et al (2008) Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol 32:1029–1037PubMedCrossRefGoogle Scholar
  139. 139.
    Ji H, Isacson C, Seidman JD et al (2002) Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21:391–400PubMedCrossRefGoogle Scholar
  140. 140.
    Jin Z, Ogata S, Tamura G et al (2003) Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 22:368–373PubMedCrossRefGoogle Scholar
  141. 141.
    Jordan SJ, Green AC, Whiteman DC et al (2007) Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiologic evidence of a neoplastic continuum? Gynecol Oncol 107:223–230PubMedCrossRefGoogle Scholar
  142. 142.
    Karam AK, Stempel M, Barakat R et al (2009) Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass. Gynecol Oncol 112:490–495PubMedCrossRefGoogle Scholar
  143. 143.
    Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRefGoogle Scholar
  144. 144.
    Khalifeh I, Munkarah AR, Lonardo F et al (2004) Expression of cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and ovarian serous carcinoma. Int J Gynecol Pathol 23:162–169PubMedCrossRefGoogle Scholar
  145. 145.
    Khalifeh I, Munkarah AR, Schimp V et al (2005) The impact of c-Kit and Ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol 24:228–234PubMedCrossRefGoogle Scholar
  146. 146.
    Khedmati F, Chirolas C, Seidman JD (2009) Ovarian and paraovarian squamous-lined cysts (epidermoid cysts): a clinicopathologic study of 18 cases with comparison to mature cystic teratomas. Int J Gynecol Pathol 28:193–196PubMedCrossRefGoogle Scholar
  147. 147.
    Khunamornpong S, Suprasert P, Na Chiangmai W et al (2006) Metastatic tumors to the ovaries: a study of 170 cases in Northern Thailand. Int J Gynecol Cancer 16(suppl 1):132–138PubMedCrossRefGoogle Scholar
  148. 148.
    Kim KR, Lee HI, Lee SK et al (2007) Is stromal microinvasion in primary mucinous ovarian tumors with “mucin granuloma” true invasion? Am J Surg Pathol 31:546–554PubMedCrossRefGoogle Scholar
  149. 149.
    Kindelberger DW, Lee Y, Miron A et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169PubMedCrossRefGoogle Scholar
  150. 150.
    King BL, Carcangiu ML, Carter D et al (1995) Microsatellite instability in ovarian neoplasms. Br J Cancer 72:376–382PubMedCrossRefGoogle Scholar
  151. 151.
    Klaren HM, van’t Veer LJ, van Leeuwen FE et al (2003) Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 95:941–947PubMedCrossRefGoogle Scholar
  152. 152.
    Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43PubMedCrossRefGoogle Scholar
  153. 153.
    Kobayashi H, Yamada Y, Sado T et al (2008) A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 18:414–420PubMedCrossRefGoogle Scholar
  154. 154.
    Kobel M, Kalloger SE, Baker PM et al (2010) Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 34:984–993PubMedCrossRefGoogle Scholar
  155. 155.
    Kobel M, Kalloger SE, Carrick J et al (2009) A limited panel of immunomarkers can reliably distinguish clear cell and high grade serous carcinoma of the ovary. Am J Surg Pathol 33:14–21PubMedCrossRefGoogle Scholar
  156. 156.
    Kobel M, Xu H, Bourne PA et al (2009) IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathol 22:469–475CrossRefGoogle Scholar
  157. 157.
    Kolasa IK, Rembiszewska A, Janiec-Jankowska A et al (2006) PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 103:692–697PubMedCrossRefGoogle Scholar
  158. 158.
    Kommoss F, Kommoss S, Schmidt D et al (2005) Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 97:195–199PubMedCrossRefGoogle Scholar
  159. 159.
    Korner M, Burckhardt E, Mazzucchelli L (2006) Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma. Modern Pathol 19:1615–1623CrossRefGoogle Scholar
  160. 160.
    Kraus JA, Seidman JD (2010) The relationship between papillary infarction and microinvasion in ovarian atypical proliferative (“borderline”) serous and seromucinous tumors. Int J Gynecol Pathol 29:303–309PubMedCrossRefGoogle Scholar
  161. 161.
    Krishnamurti U, Sasatomi E, Swalsky PA et al (2005) Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol 24:56–61PubMedGoogle Scholar
  162. 162.
    Kubba LA, McCluggage WG, Liu J et al (2008) Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Modern Pathol 21:485–490CrossRefGoogle Scholar
  163. 163.
    Kumaran GC, Jayson GC, Clamp AR (2009) Antiangiogenic drugs in ovarian cancer. Br J Cancer 100:1–7PubMedCrossRefGoogle Scholar
  164. 164.
    Kuo KT, Buan B, Feng Y et al (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036–4042PubMedCrossRefGoogle Scholar
  165. 165.
    Kuo KT, Mao TL, Jones S et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601PubMedCrossRefGoogle Scholar
  166. 166.
    Kurian AW, Balise RR, McGuire V et al (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96:520–530PubMedCrossRefGoogle Scholar
  167. 167.
    Kurman RJ, Shih I-M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160PubMedGoogle Scholar
  168. 168.
    Kurman RJ, Shih I-M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRefGoogle Scholar
  169. 169.
    Kurman RJ, Trimble CL (1993) The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12:120–127PubMedCrossRefGoogle Scholar
  170. 170.
    Kurman RJ, Visvanathan K, Roden R et al (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351–356PubMedCrossRefGoogle Scholar
  171. 171.
    Laki F, Kirova YM, This P et al (2007) Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109:1784–1790PubMedCrossRefGoogle Scholar
  172. 172.
    Lamb JD, Garcia RL, Goff BA et al (2006) Predictors of occultneoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 194:1702–1709PubMedCrossRefGoogle Scholar
  173. 173.
    Le T, Shahriari P, Hopkins L et al (2006) Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer 16:986–990PubMedCrossRefGoogle Scholar
  174. 174.
    Lee CH, Huntsman DG, Cheang MCU et al (2005) Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24:147–152PubMedCrossRefGoogle Scholar
  175. 175.
    Lee KW, Kang NJ, Heo YS et al (2008) Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 68:946–955PubMedCrossRefGoogle Scholar
  176. 176.
    Lee ES, Leong AS-Y, Kim Y-S et al (2006) Calretinin, CD34 and α–smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary. Modern Pathol 19:364–372CrossRefGoogle Scholar
  177. 177.
    Lee KR, Nucci MR (2003) Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol 22:42–51PubMedCrossRefGoogle Scholar
  178. 178.
    Lee P, Rosen DG, Zhu C et al (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96:671–677PubMedCrossRefGoogle Scholar
  179. 179.
    Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxoma peritonei”. Am J Surg Pathol 24:1447–1464PubMedCrossRefGoogle Scholar
  180. 180.
    Leeper K, Garcia R, Swisher C et al (2002) Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87:52–56PubMedCrossRefGoogle Scholar
  181. 181.
    Leiser AL, Chi DS, Ishill NM et al (2007) Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 105:657–661PubMedCrossRefGoogle Scholar
  182. 182.
    Leitao MM, Boyd J, Hummer A et al (2004) Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28:147–159PubMedCrossRefGoogle Scholar
  183. 183.
    Leitao MM, Soslow RA, Baergen RN et al (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 93:301–306PubMedCrossRefGoogle Scholar
  184. 184.
    Levine DA, Argenta PA, Yee CJ et al (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222–4227PubMedCrossRefGoogle Scholar
  185. 185.
    Lewis MR, Deavers MT, Silva EG et al (2006) Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol 30:177–184PubMedCrossRefGoogle Scholar
  186. 186.
    Liu J, Albarracin CT, Chang K-H et al (2004) Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Modern Pathol 17:75–80CrossRefGoogle Scholar
  187. 187.
    Logani S, Oliva E, Amin MB et al (2003) Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 27:1434–1441PubMedCrossRefGoogle Scholar
  188. 188.
    Loizzi V, Cormio G, Resta L et al (2005) Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 15:217–223PubMedCrossRefGoogle Scholar
  189. 189.
    Loizzi V, Rossi C, Cormio G et al (2005) Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer 15:26–31PubMedCrossRefGoogle Scholar
  190. 190.
    Longacre TA, McKenney JK, Tazelaar HD et al (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (>5-year) follow-up. Am J Surg Pathol 29:707–723PubMedCrossRefGoogle Scholar
  191. 191.
    Longacre TA, Oliva E, Soslow RA (2007) Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol 338:1160–1163Google Scholar
  192. 192.
    Lu KH, Bell DA, Welch WR et al (1998) Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58:2328–2330PubMedGoogle Scholar
  193. 193.
    Lu KH, Garber JE, Cramer DW et al (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728–2732PubMedGoogle Scholar
  194. 194.
    Lugli A, Forster Y, Haas P et al (2003) Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol 34:994–1000PubMedCrossRefGoogle Scholar
  195. 195.
    Malander S, Rambech E, Kristoffersson U et al (2006) The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101:238–243PubMedCrossRefGoogle Scholar
  196. 196.
    Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRefGoogle Scholar
  197. 197.
    Malpica A, Deavers MT, Tornos C et al (2007) Introbserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174PubMedCrossRefGoogle Scholar
  198. 198.
    Mano MS, Rosa DD, Azambuja E et al (2007) Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 17:316–324PubMedCrossRefGoogle Scholar
  199. 199.
    Markman M (2009) Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluation. Gynecol Oncol 113:4–5PubMedCrossRefGoogle Scholar
  200. 200.
    Marquez RT, Baggerly KA, Patterson AP et al (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11:6116–6126PubMedCrossRefGoogle Scholar
  201. 201.
    Matias-Guiu X, Lagarda H, Catasus L et al (2002) Clonality analysis in synchronous or metachronous tumors of the female genital tract. Int J Gynecol Pathol 21:205–211PubMedCrossRefGoogle Scholar
  202. 202.
    Matsuura Y, Robertson G, Marsden DE et al (2007) Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 104:406–410PubMedCrossRefGoogle Scholar
  203. 203.
    Mayr D, Hirschmann A, Lohrs U et al (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103:883–887PubMedCrossRefGoogle Scholar
  204. 204.
    Mayr D, Kanitz V, Anderegg B et al (2006) Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126:101–109PubMedCrossRefGoogle Scholar
  205. 205.
    McCluggage WG (2004) WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 23:97–99, editorialPubMedCrossRefGoogle Scholar
  206. 206.
    McCluggage WG (2006) Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 25:101–120PubMedCrossRefGoogle Scholar
  207. 207.
    McCluggage WG (2008) My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 61:152–163PubMedCrossRefGoogle Scholar
  208. 208.
    McCluggage WG, Ganesan R, Herrington CS (2009) Endometrial stromal sarcomas with extensive endometrioid glandular differentiation: report of a series with emphasis on the potential for misdiagnosis and discussion of the differential diagnosis. Histopathology 54:365–373PubMedCrossRefGoogle Scholar
  209. 209.
    McKenney JK, Balzer BL, Longacre TA (2006) Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 30:614–624PubMedCrossRefGoogle Scholar
  210. 210.
    McKenney JK, Balzer BL, Longacre TA (2006) Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol 30:1209–1221PubMedCrossRefGoogle Scholar
  211. 211.
    McKenney JK, Soslow RA, Longacre TA (2008) Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol 32:645–655PubMedCrossRefGoogle Scholar
  212. 212.
    Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236PubMedCrossRefGoogle Scholar
  213. 213.
    National Health and Medical Research Council, Australian Government. Clinical practice guidelines for the management of women with ovarian cancer. http://www.nhmrc.gov.au/publications/synopses/_files/cp98_2.pdf. Accessed 6 Oct 2008
  214. 214.
    Meeuwissen PAM, Seynaeve C, Brekelmans CTM et al (2005) Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97:476–482PubMedCrossRefGoogle Scholar
  215. 215.
    Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053–1065PubMedCrossRefGoogle Scholar
  216. 216.
    Melichar B, Urminska H, Kohlova T et al (2004) Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol 94:267–276PubMedCrossRefGoogle Scholar
  217. 217.
    Menczer J, Liphshitz I, Barchana M (2006) A decreasing incidence of ovarian carcinoma in Israel. Int J Gynecol Cancer 16:41–44PubMedCrossRefGoogle Scholar
  218. 218.
    Meng Q, Xia C, Fang J et al (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18:2262–2271PubMedCrossRefGoogle Scholar
  219. 219.
    Menon U, Gentry-Maharaj A, Hallett R et al (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327–340PubMedCrossRefGoogle Scholar
  220. 220.
    Merajver SD, Pham TM, Caduff RF et al (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 9:439–443PubMedCrossRefGoogle Scholar
  221. 221.
    Miller K, Price JH, Dobbs SP et al (2008) An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol 61:652–657PubMedCrossRefGoogle Scholar
  222. 222.
    Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: results from the SEER program, 1978-1998. Cancer 95:2380–2389PubMedCrossRefGoogle Scholar
  223. 223.
    Misdraji J, Vaidya A, Tambouret RH et al (2006) Psammoma bodies in cervicovaginal cytology specimens: a clinicopathological analysis of 31 cases. Gynecol Oncol 103:238–246PubMedCrossRefGoogle Scholar
  224. 224.
    Mizuno M, Kikkawa F, Shibata K et al (2003) Long-term prognosis of stage I ovarian carcinoma: prognostic importance of intraoperative rupture. Oncology 65:29–36PubMedCrossRefGoogle Scholar
  225. 225.
    Mok SC, Bell DA, Knapp RC et al (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489–1492PubMedGoogle Scholar
  226. 226.
    Morice P, Camatte S, Rey A et al (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 14:592–598PubMedCrossRefGoogle Scholar
  227. 227.
    Movahedi-Lankarani S, Kurman RJ (2002) Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol 26:1477–1483PubMedCrossRefGoogle Scholar
  228. 228.
    Nagai Y, Kishimoto T, Nikaido T et al (2003) Squamous predominance in mixed- epithelial papillary cystadenomas of borderline malignancy of mullerian type arising in endometriotic cysts: a study of four cases. Am J Surg Pathol 27:242–247PubMedCrossRefGoogle Scholar
  229. 229.
    Nakatsuka S, Oji Y, Horiuchi T et al (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Modern Pathol 19:804–814Google Scholar
  230. 230.
    Nakayama K, Nakayama N, Jinawath N et al (2007) Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120:2613–2617PubMedCrossRefGoogle Scholar
  231. 231.
    Nakayama K, Nakayama N, Kurman RJ et al (2006) Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5:779–785PubMedCrossRefGoogle Scholar
  232. 232.
    National Cancer Institute and National Human Genome Research Institute. The cancer genome atlas. http://cancergenome.nih.gov/. Accessed 11 July 2010
  233. 233.
    Ness RB, Modugno F (2006) Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur J Cancer 42:691–703PubMedCrossRefGoogle Scholar
  234. 234.
    Nishimura S, Tsuda H, Ito K et al (2007) Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol 38:134–139PubMedCrossRefGoogle Scholar
  235. 235.
    Nomura K, Aizawa S (2000) Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: a clinicopathologic analysis of 40 cases. Cancer 89:1541–1546PubMedCrossRefGoogle Scholar
  236. 236.
    Nomura K, Aizawa S, Hano H (2004) Ovarian mucinous borderline tumors of intestinal type without intraepithelial carcinoma: are they still tumors of low malignant potential? Pathol Int 54:420–424PubMedCrossRefGoogle Scholar
  237. 237.
    O’Neill CJ, Deavers MT, Malpica A et al (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol 29:1034–1041PubMedGoogle Scholar
  238. 238.
    Obata K, Morland SJ, Watson RH et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097PubMedGoogle Scholar
  239. 239.
    Obermair A, Fuller A, Lopez-Varela E et al (2007) A new prognostic model for FIGO stage I epithelial ovarian cancer. Gynecol Oncol 104:607–611PubMedCrossRefGoogle Scholar
  240. 240.
    Oda K, Stokoe D, Taketani Y et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669–10673PubMedCrossRefGoogle Scholar
  241. 241.
    Ohira S, Itoh K, Shiozawa T et al (2004) Ovarian non-small cell neuroendocrine carcinoma with paraneoplastic parathyroid hormone-related hypercalcemia. Int J Gynecol Pathol 23:39–397CrossRefGoogle Scholar
  242. 242.
    Ohta Y, Suzuki T, Shiokawa A et al (2005) Expression of CD10 and cytokeratins in ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 24:239–245PubMedCrossRefGoogle Scholar
  243. 243.
    Oliva E, Branton PA, Scully RE (2005) Ovary. College of American Pathologists. http://cap.org. Accessed 12 May 2009
  244. 244.
    Oliva E, Branton PA, Scully RE (2005) Peritoneum. College of American Pathologists. http://cap.org
  245. 245.
    Olivier RI, van Beurden M, Lubsen MA et al (2004) Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90:1492–1497PubMedCrossRefGoogle Scholar
  246. 246.
    Ordonez NG (2000) Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology 36:433–438PubMedCrossRefGoogle Scholar
  247. 247.
    Ordonez NG (2005) Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 36:1163–1167PubMedCrossRefGoogle Scholar
  248. 248.
    Ordonez NG (2007) What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 38:1–16PubMedCrossRefGoogle Scholar
  249. 249.
    Orsulic S, Li Y, Soslow RA, Vitale-Cross LA et al (2002) Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53–62PubMedCrossRefGoogle Scholar
  250. 250.
    Ozols RF, Rubin SC, Thomas GM et al (2005) Epithelial ovarian cancer. In: Hoskins WJ et al (eds) Principles and practice of gynecologic oncology, 4th edn. Lippincott, New York, pp 895–987Google Scholar
  251. 251.
    Pal T, Permuth-Wey J, Kumar A et al (2008) Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 14:6847–6854PubMedCrossRefGoogle Scholar
  252. 252.
    Park JY, Kim DY, Kim JH et al (2009) Surgical management of borderline ovarian tumors: the role of fertility sparing surgery. Gynecol Oncol 113:75–82PubMedCrossRefGoogle Scholar
  253. 253.
    Partridge E, Kreimer AR, Greenlee RT et al (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113:775–782PubMedGoogle Scholar
  254. 254.
    Pather S, Quinn MA (2004) Clear cell cancer of the ovary – is it chemosensitive? Int J Gynecol Cancer 15:432–437CrossRefGoogle Scholar
  255. 255.
    Pectasides D, Fountzilas G, Aravantinos G et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285–291PubMedCrossRefGoogle Scholar
  256. 256.
    Pectasides D, Pectasides A, Psyrri A et al (2006) Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11:1089–1094PubMedCrossRefGoogle Scholar
  257. 257.
    Petit T, Velten M, d’Hombres A et al (2007) Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 104:104–108PubMedCrossRefGoogle Scholar
  258. 258.
    Piek JMJ, Kenemans P, Verheijen RHM (2004) Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 191:718–732PubMedCrossRefGoogle Scholar
  259. 259.
    Pohl G, Ho CL, Kurman RJ, Bristow R et al (2005) Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994–2000PubMedCrossRefGoogle Scholar
  260. 260.
    Poli Neto OB, Candido Dos Reis FJ, Zambelli-Ramalho LN et al (2006) p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer 16:152–155PubMedCrossRefGoogle Scholar
  261. 261.
    Powell CB, Kenley E, Chen L et al (2005) Risk-reducing salpingo-oophorect omy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132PubMedCrossRefGoogle Scholar
  262. 262.
    Prat J, de Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26:1111–1128PubMedCrossRefGoogle Scholar
  263. 263.
    Prat J, Ribe A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36:861–870PubMedCrossRefGoogle Scholar
  264. 264.
    Prentice RL, Thomson CA, Caan B et al (2007) Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative dietary modification randomized controlled trial. J Natl Cancer Inst 99:1534–1543PubMedCrossRefGoogle Scholar
  265. 265.
    Press JZ, De Luca A, Boyd N et al (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17PubMedCrossRefGoogle Scholar
  266. 266.
    Pusiol T, Parolari A, Piscioli I et al (2008) Prevalence of and significance of psammoma bodies in cervicovaginal smears in a cervical cancer screening program with emphasis on a case of primary bilateral ovarian psammocarcinoma. Cytojournal 5:7PubMedCrossRefGoogle Scholar
  267. 267.
    Ramalingam P, Malpica A, Silva EG et al (2004) The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol 28:1499–1505PubMedCrossRefGoogle Scholar
  268. 268.
    Ramus SJ, Harrington PA, Pye C et al (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28:1207–1215PubMedCrossRefGoogle Scholar
  269. 269.
    Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRefGoogle Scholar
  270. 270.
    Ricci R, Komminoth P, Bannwart F et al (2003) PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus. Diagn Mol Pathol 12:71–78PubMedCrossRefGoogle Scholar
  271. 271.
    Riedel I, Czernobilsky B, Lifschitz-Mercer B et al (2001) Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers including cytokeratins and uroplakins. Virchows Archiv 438:181–191PubMedCrossRefGoogle Scholar
  272. 272.
    Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRefGoogle Scholar
  273. 273.
    Rodriguez IM, Irving JA, Prat J (2004) Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 28:1311–1318PubMedCrossRefGoogle Scholar
  274. 274.
    Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26:139–152PubMedCrossRefGoogle Scholar
  275. 275.
    Rollins SE, Young RH, Bell DA (2006) Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma. Am J Surg Pathol 30:457–462PubMedCrossRefGoogle Scholar
  276. 276.
    Roma AA, Malpica A, Deavers MT, Silva EG (2008). Ovarian serous borderline tumors with a predominant micropapillary pattern are aggressive neoplasms with an increased risk for low grade serous carcinoma. Modern Pathol 21:221A. AbstractGoogle Scholar
  277. 277.
    Ronnett BM, Kajdacsy-Balla A, Gilks CB et al (2004) Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 35:949–960PubMedCrossRefGoogle Scholar
  278. 278.
    Ronnett BM, Kurman RJ, Zahn CM et al (1995) Pseudomyxoma peritonei in women: A clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 26:509–524PubMedCrossRefGoogle Scholar
  279. 279.
    Ronnett BM, Seidman JD (2003) Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 27:650–657PubMedCrossRefGoogle Scholar
  280. 280.
    Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91PubMedCrossRefGoogle Scholar
  281. 281.
    Ronnett BM, Zahn CM, Kurman RJ (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19:1390–1408PubMedCrossRefGoogle Scholar
  282. 282.
    Roth LM, Emerson RE, Ulbright TM (2003) Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol 27:1253–1259PubMedCrossRefGoogle Scholar
  283. 283.
    Rufford B, Jacobs IJ (2004) Screening and diagnosis of ovarian cancer in the general population. In: Gershenson DM et al (eds) Gynecologic cancer: controversies in management. Elsevier, Philadelphia, pp 355–368CrossRefGoogle Scholar
  284. 284.
    Russo A, Calo V, Bruno L et al (2009) Hereditary ovarian cancer. Crit Rev Oncol Hematol 69:28–44PubMedCrossRefGoogle Scholar
  285. 285.
    Sainz de la Cuesta R, Eichhorn JH, Rice LW et al (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60:238–244PubMedCrossRefGoogle Scholar
  286. 286.
    Salani R, Kurman RJ, Giuntoli R 2nd et al (2008) Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 18:487–491PubMedCrossRefGoogle Scholar
  287. 287.
    Salvador S, Gilks B, Kobel M et al (2009) The fallopian tube: primary site of most pelvic high grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRefGoogle Scholar
  288. 288.
    Sangha N, Wu R, Kuick R et al (2008) Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia 10:1362–1372PubMedGoogle Scholar
  289. 289.
    Sangoi AR, McKenney JK, Dadras SS et al (2008) Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study. Am J Surg Pathol 32:261–268PubMedCrossRefGoogle Scholar
  290. 290.
    Sangoi AR, Soslow RA, Teng NN et al (2008) Ovarian clear cell carcinomas with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol 32:269–274PubMedCrossRefGoogle Scholar
  291. 291.
    Sassen S, Schmalfeldt B, Avril N et al (2007) Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced stage ovarian cancer. Hum Pathol 38:926–934PubMedCrossRefGoogle Scholar
  292. 292.
    Sato N, Tsunoda H, Nishida M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMedGoogle Scholar
  293. 293.
    Schaner ME, Ross DT, Ciaravino G et al (2003) Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14:4376–4386PubMedCrossRefGoogle Scholar
  294. 294.
    Schmeler KM, Lynch HT, Chen L et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269PubMedCrossRefGoogle Scholar
  295. 295.
    Schmeler KM, Sun CC, Bodurka DC et al (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108:510–514PubMedCrossRefGoogle Scholar
  296. 296.
    Schwartz DR, Kardia SL, Shedden KA et al (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62:4722–4729PubMedGoogle Scholar
  297. 297.
    Scully RE, Sobin LH et al (1999) Histological typing of ovarian tumours, 2nd edn. Springer, New YorkCrossRefGoogle Scholar
  298. 298.
    Seidman JD (1996) Prognostic importance of atypia and hyperplasia in endometriosis. Int J Gynecol Pathol 15:1–9PubMedCrossRefGoogle Scholar
  299. 299.
    Seidman JD, Cosin JA, Wang B et al (2010) Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted. A clinicopathologic study of 84 patients originally classified as FIGO stage II. Gynecol Oncol (2010), doi:10.1016/j.ygyno.2010.07.002. Accessed 15 July 2010Google Scholar
  300. 300.
    Seidman JD, Horkayne-Szakaly I, Cosin JA et al (2006) Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 103:703–708PubMedCrossRefGoogle Scholar
  301. 301.
    Seidman JD, Horkayne-Szakaly I, Haiba M et al (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41–44PubMedCrossRefGoogle Scholar
  302. 302.
    Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) tumors: a study of 120 tumors. Arch Pathol Lab Med 132:1753–1760PubMedGoogle Scholar
  303. 303.
    Seidman JD, Kraus JA, Yemelyanova A et al (2009) Ovarian low grade serous neoplasms: evaluation of sampling recommendations based on tumors expected to have invasion (those with peritoneal invasive low grade serous carcinoma (invasive implants)). Modern Pathol 22(Suppl 1):236A, AbstractGoogle Scholar
  304. 304.
    Seidman JD, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20:1331–1345PubMedCrossRefGoogle Scholar
  305. 305.
    Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539–557PubMedCrossRefGoogle Scholar
  306. 306.
    Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27:985–993PubMedCrossRefGoogle Scholar
  307. 307.
    Seidman JD, Mehrotra A (2005) Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous “cystadenomas” and “cystadenofibromas”. Gynecol Oncol 96:395–401PubMedCrossRefGoogle Scholar
  308. 308.
    Seidman JD, Russell P, Kurman RJ (2002) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract, 5th edn. Springer, New York, pp 791–904Google Scholar
  309. 309.
    Seidman JD, Sherman ME, Bell KA et al (2002) Salpingitis, salpingoliths and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRefGoogle Scholar
  310. 310.
    Seidman JD, Soslow RA, Vang R et al (2004) Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35:918–933PubMedCrossRefGoogle Scholar
  311. 311.
    Seidman JD, Varallo MR (2007) Micropapillary serous carcinoma: the solution to the ovarian borderline tumor conundrum. Pathol Case Rev 12:136–142CrossRefGoogle Scholar
  312. 312.
    Seidman JD, Wang B (2007) Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma. Gynecol Oncol 106:201–206PubMedCrossRefGoogle Scholar
  313. 313.
    Seidman JD, Yemelyanova AV, Khedmati F et al (2010) Prognostic factors for stage I ovarian carcinoma. Int J Gynecol Pathol 29:1–7Google Scholar
  314. 314.
    Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ. The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol, in pressGoogle Scholar
  315. 315.
    Senkel S, Lucas B, Klein-Hitpass L et al (2005) Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731:179–190PubMedCrossRefGoogle Scholar
  316. 316.
    Shappell HW, Riopel MA, Smith-Sehdev AE et al (2002) Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinoma. Am J Surg Pathol 26:1529–1541PubMedCrossRefGoogle Scholar
  317. 317.
    Shaw P, McLaughlin JR, Zweemer RP et al (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21:407–411PubMedCrossRefGoogle Scholar
  318. 318.
    Shedden KA, Kshirsagar MP, Schwartz DR et al (2005) Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 11:2123–2131PubMedCrossRefGoogle Scholar
  319. 319.
    Sherman ME, Berman J, Birrer MJ et al (2004) Current challenges and opportunities for research on borderline ovarian tumors. Human Pathol 35:961–970CrossRefGoogle Scholar
  320. 320.
    Sherman ME, Mink PJ, Curtis R et al (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100:1045–1052PubMedCrossRefGoogle Scholar
  321. 321.
    Shvartsman HS, Sun CC, Bodurka DC et al (2007) Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low grade serous carcinoma. Gynecol Oncol 105:625–629PubMedCrossRefGoogle Scholar
  322. 322.
    Sieben NL, Kolkman-Uljee SM et al (2003) Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol 162:1095–1101PubMedCrossRefGoogle Scholar
  323. 323.
    Sieben NL, Macropoulos P, Roemen GM et al (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202:336–340PubMedCrossRefGoogle Scholar
  324. 324.
    Silasi DA, Illuzzi JL, Kelly MG et al (2008) Carcinosarcoma of the ovary. Int J Gynecol Cancer 18:22–29PubMedCrossRefGoogle Scholar
  325. 325.
    Silva EG, Deavers MT, Bodurka DC et al (2006) Association of low grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 25:52–58PubMedCrossRefGoogle Scholar
  326. 326.
    Silva EG, Gershenson DM, Malpica A et al (2006) The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time-dependent. Am J Surg Pathol 30:1367–1371PubMedCrossRefGoogle Scholar
  327. 327.
    Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486PubMedCrossRefGoogle Scholar
  328. 328.
    Singer G, Stohr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRefGoogle Scholar
  329. 329.
    Skirnisdottir I, Seidal T, Karlsson MG et al (2005) Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 26:177–183PubMedGoogle Scholar
  330. 330.
    Slomovitz BM, Caputo TA, Gretz HF et al (2002) A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol 26:592–600PubMedCrossRefGoogle Scholar
  331. 331.
    Smith-Sehdev AE, Sehdev PS, Kurman RJ (2003) Noninvasive and invasive micropapillary (low grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 27:725–736PubMedCrossRefGoogle Scholar
  332. 332.
    Soliman PT, Slomovitz BM, Broaddus RR et al (2004) Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94:456–462PubMedCrossRefGoogle Scholar
  333. 333.
    Soslow RA (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27:161–174PubMedGoogle Scholar
  334. 334.
    Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300PubMedCrossRefGoogle Scholar
  335. 335.
    Stadlmann S, Gueth U, Reiser U et al (2006) Epithelial growth factor status in primary and recurrent ovarian cancer. Modern Pathol 19:607–610CrossRefGoogle Scholar
  336. 336.
    Stern RC, Dash R, Bentley RC et al (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20:133–139PubMedCrossRefGoogle Scholar
  337. 337.
    Stewart BW, Kleihues P et al (eds) (2003) World cancer report. World Health Organization International Agency for Research on Cancer Press, Lyon, p 219Google Scholar
  338. 338.
    Storey DJ, Rush R, Stewart M et al (2008) Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center. Cancer 112:2211–2220PubMedCrossRefGoogle Scholar
  339. 339.
    Suehiro Y, Sakamoto M, Umayahara K et al (2000) Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59:50–56PubMedCrossRefGoogle Scholar
  340. 340.
    Surveillance, Epidemiology, End Results (SEER). http://www.seer.cancer.gov/statfacts/html/ovary.html?statfacts_page=ovary.html&x=15&y=17. Accessed 9 Mar 2008
  341. 341.
    Suzuki S, Kajiyama H, Shibata K (2008) Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol 19:1284–1287PubMedCrossRefGoogle Scholar
  342. 342.
    Tabrizi AD, Kalloger SE, Kobel M et al (2010) Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 29:99–107PubMedCrossRefGoogle Scholar
  343. 343.
    Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRefGoogle Scholar
  344. 344.
    Tam KF, Cheung ANY, Liu KL et al (2003) A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol Oncol 91:603–607PubMedCrossRefGoogle Scholar
  345. 345.
    Tan DSP, Kaye S (2007) Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 60:355–360PubMedCrossRefGoogle Scholar
  346. 346.
    Tanaka T, Tomaru Y, Nomura Y et al (2004) Comprehensive search for HNF-1beta-regulated genes in mouse hepatoma cells perturbed by transcription regulatory factor-targeted RNAi. Nucleic Acids Res 32:2740–2750PubMedCrossRefGoogle Scholar
  347. 347.
    Tangjitgamol S, Levenback CF, Beller U et al (2004) Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 14:399–422PubMedCrossRefGoogle Scholar
  348. 348.
    Tanner EJ, Zahurak ML, Bristow RE et al (2008) Surgical care of young women diagnosed with ovarian cancer: a population-based perspective. Gynecol Oncol 111:221–225PubMedCrossRefGoogle Scholar
  349. 349.
    Tapper J, Butzow R, Wahlstrom T et al (1997) Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 75:1782–1787PubMedCrossRefGoogle Scholar
  350. 350.
    Tetsche MS, Dethlefsen C, Pedersen L, Sorenson HT, Norgaard M (2008) The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8:31PubMedCrossRefGoogle Scholar
  351. 351.
    Thomas EJ, Campbell IG (2000) Molecular genetic defects in endometriosis. Gynecol Obstet Invest 50(Suppl 1):44–50PubMedCrossRefGoogle Scholar
  352. 352.
    Thrall M, Gallion HH, Kryscio R et al (2006) BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 16(suppl 1):166–171PubMedCrossRefGoogle Scholar
  353. 353.
    Timmers PJ, Zwinderman AH, Teodorovic I et al (2009) Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer 19:88–93PubMedCrossRefGoogle Scholar
  354. 354.
    Tochigi N, Kishimoto T, Supriatna Y et al (2003) Hepatoid carcinoma of the ovary: a report of three cases admixed with a common surface epithelial carcinoma. Int J Gynecol Pathol 22:266–271PubMedCrossRefGoogle Scholar
  355. 355.
    Tornos C, Soslow R, Chen S et al (2005) Expression of WT1, CA 125 and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 29:1482–1489PubMedCrossRefGoogle Scholar
  356. 356.
    Tsuchiya A, Sakamoto M, Yasuda J et al (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503–2512PubMedCrossRefGoogle Scholar
  357. 357.
    Tsuda H, Ito YM, Ohashi Y et al (2005) Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11:6880–6888PubMedCrossRefGoogle Scholar
  358. 358.
    Tworoger SS, Gertig DM, Gates MA et al (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112:1169–1177PubMedCrossRefGoogle Scholar
  359. 359.
    van der Velde NM, Mourits MJ, Arts HJ et al (2009) Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124:919–923PubMedCrossRefGoogle Scholar
  360. 360.
    Van Nagell JR jr, DePriest PD, Ueland FR et al (2007) Ovarian cancer screening with annual transvaginal sonography: findings of 25000 women screened. Cancer 109:1887–1896PubMedCrossRefGoogle Scholar
  361. 361.
    Vang R, Gown AM, Barry TS et al (2006) Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 25:83–89PubMedCrossRefGoogle Scholar
  362. 362.
    Vang R, Gown AM, Barry TS et al (2006) Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 30:1130–1139PubMedCrossRefGoogle Scholar
  363. 363.
    Vang R, Gown AM, Barry TS et al (2006) Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 19:97–105PubMedCrossRefGoogle Scholar
  364. 364.
    Vang R, Gown AM, Farinola M et al (2007) p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 31:653–663PubMedCrossRefGoogle Scholar
  365. 365.
    Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRefGoogle Scholar
  366. 366.
    Vang R, Gown AM, Zhao C et al (2007) Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 31:854–869PubMedCrossRefGoogle Scholar
  367. 367.
    Vang R, Shih I-M, Salani R et al (2008) Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 32:1667–1674PubMedCrossRefGoogle Scholar
  368. 368.
    Veras E, Deavers MT, Silva EG et al (2007) Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol 31:774–782PubMedCrossRefGoogle Scholar
  369. 369.
    Veras E, Mao T-L, Ayhan A et al (2009) Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 33:844–853PubMedCrossRefGoogle Scholar
  370. 370.
    Vernooij F, Heintz APM, Witteveen PO et al (2008) Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. J Natl Cancer Inst 100:399–406PubMedCrossRefGoogle Scholar
  371. 371.
    Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedCrossRefGoogle Scholar
  372. 372.
    Wang C, Horiuchi A, Imai T et al (2004) Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202:215–223PubMedCrossRefGoogle Scholar
  373. 373.
    Watson P, Butzow R, Lynch HT et al (2001) The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223–228PubMedCrossRefGoogle Scholar
  374. 374.
    Wells M (2004) Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. Int Gynecol Pathol 23:316–320CrossRefGoogle Scholar
  375. 375.
    Werness BA, Ramus SJ, DiCioccio RA et al (2004) Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 23:29–34PubMedCrossRefGoogle Scholar
  376. 376.
    Willner J, Wurz K, Allison KH et al (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38:607–613PubMedCrossRefGoogle Scholar
  377. 377.
    Wimberger P, Lehmann N, Kimmig R et al (2006) Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 100:300–307PubMedCrossRefGoogle Scholar
  378. 378.
    Winter WE, Maxwell L, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627PubMedCrossRefGoogle Scholar
  379. 379.
    Wong KK (2009) Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway. Recent Patents Anticancer Drug Discov 4:28–35CrossRefGoogle Scholar
  380. 380.
    Wong HF, Low JJH, Chua Y et al (2007) Ovarian tumors of borderline malignancy: a review of 247 patients from 1991–2004. Int J Gynecol Cancer 17:342–349PubMedCrossRefGoogle Scholar
  381. 381.
    Wong K-K, Lu KH, Malpica A et al (2007) Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 26:404–409PubMedCrossRefGoogle Scholar
  382. 382.
    Wright K, Wilson P, Morland S et al (1999) Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 82:625–629PubMedCrossRefGoogle Scholar
  383. 383.
    Wu R, Hendrix-Lucas N, Kuick R et al (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/B-catanin and PI3K/Pten signaling pathways. Cancer Cell 11:321–333PubMedCrossRefGoogle Scholar
  384. 384.
    Yamamoto S, Tsuda H, Aida S et al (2007) Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 38:1074–1080PubMedCrossRefGoogle Scholar
  385. 385.
    Yamamoto S, Tsuda H, Kita T et al (2007) Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virch Arch 451:27–35CrossRefGoogle Scholar
  386. 386.
    Yamamoto S, Tsuda H, Takano M et al (2008) Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative clear-cell carcinogenic pathway. J Pathol 216:103–110PubMedGoogle Scholar
  387. 387.
    Yamamoto S, Tsuda H, Yoshikawa T et al (2007) Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 31:999–1006PubMedCrossRefGoogle Scholar
  388. 388.
    Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–492PubMedCrossRefGoogle Scholar
  389. 389.
    Yemelyanova AV, Cosin JA, Bidus MA (2008) Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer 18:465–469PubMedCrossRefGoogle Scholar
  390. 390.
    Yemelyanova A, Mao T-L, Nakayama N (2008) Low grade serous carcinoma of the ovary displaying a macropapillary pattern. Am J Surg Pathol 32:1800–1806PubMedCrossRefGoogle Scholar
  391. 391.
    Yemelyanova AV, Vang R, Judson K et al (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRefGoogle Scholar
  392. 392.
    Yoshikawa H, Jimbo H, Okada S et al (2000) Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest 50(Suppl 1):11–17PubMedCrossRefGoogle Scholar
  393. 393.
    Young RC, Brady MF, Nieberg RK et al (2003) Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin- a Gynecologic Oncology Group study. J Clin Oncol 21:4350–4355PubMedCrossRefGoogle Scholar
  394. 394.
    Zaino R, Whitney C, Brady MF et al (2001) Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases – a Gynecologic Oncology Group study. Gynecol Oncol 83:355–362PubMedCrossRefGoogle Scholar
  395. 395.
    Zhao C, Bratthauer GL, Barner R et al (2007) Diagnostic utility of WT1 immunostaining in ovarian Sertoli cell tumor. Am J Surg Pathol 31:1378–1386PubMedCrossRefGoogle Scholar
  396. 396.
    Zhao C, Bratthauer GL, Barner R et al (2007) Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian Sertoli cell tumor from endometrioid tumors and carcinoid tumor: a study of 160 cases. Am J Surg Pathol 31:255–266PubMedCrossRefGoogle Scholar
  397. 397.
    Zhou B, Sun Q, Cong R et al (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108:641–651PubMedCrossRefGoogle Scholar
  398. 398.
    Zorn KK, Bonome T, Gangi L et al (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422–6430PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jeffrey D. Seidman
    • 1
    Email author
  • Kathleen R. Cho
    • 2
  • Brigitte M. Ronnett
    • 3
  • Robert J. Kurman
    • 4
  1. 1.Department of Pathology and Laboratory MedicineWashington Hospital CenterWashingtonUSA
  2. 2.Department of PathologyUniversity of Michigan Medical SchoolAnn ArborUSA
  3. 3.Department of Pathology, Division of Gynecologic PathologyJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Departments of Gynecology, Obstetrics, Pathology and Oncology, Division of Gynecologic PathologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations